润达医疗
(603108)
| 流通市值：92.12亿 | | | 总市值：92.12亿 |
| 流通股本：6.04亿 | | | 总股本：6.04亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 3,470,487,876.09 | 1,661,846,010.13 | 8,311,780,357.39 | 6,176,286,324.36 |
| 营业收入 | 3,470,487,876.09 | 1,661,846,010.13 | 8,311,780,357.39 | 6,176,286,324.36 |
| 二、营业总成本 | 3,514,567,613.8 | 1,695,369,724.19 | 7,994,783,190.57 | 5,921,641,266.47 |
| 营业成本 | 2,743,783,854.18 | 1,316,525,968.41 | 6,203,492,198.74 | 4,592,846,859.28 |
| 税金及附加 | 14,232,635.04 | 6,934,547.78 | 40,981,347.66 | 31,418,567.63 |
| 销售费用 | 369,623,684.99 | 178,199,424.07 | 840,777,045.98 | 651,353,240.05 |
| 管理费用 | 200,072,067.55 | 104,063,010.8 | 479,941,188.72 | 328,121,993.25 |
| 研发费用 | 55,211,793.34 | 25,747,739.45 | 116,156,442.1 | 81,276,813.53 |
| 财务费用 | 131,643,578.7 | 63,899,033.68 | 313,434,967.37 | 236,623,792.73 |
| 其中:利息费用 | 140,429,424.15 | 68,139,704.78 | 312,858,681.19 | 237,011,916 |
| 其中:利息收入 | 8,659,031.75 | 5,765,532.67 | 13,365,461.21 | 10,713,409.58 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | 47,447,216.74 | 20,673,577.45 | 109,820,881.18 | 97,818,515.41 |
| 资产处置收益 | -958,792.77 | 645,775.8 | 11,463,482.16 | 5,542,547.12 |
| 资产减值损失(新) | -45,795.63 | -70,183.53 | -36,170,132.75 | -3,691,816.63 |
| 信用减值损失(新) | -73,969,820.68 | -44,888,893.6 | -81,714,124.65 | -112,898,735.77 |
| 其他收益 | 20,117,157.69 | 8,056,159.19 | 33,662,573.6 | 17,031,776.28 |
| 四、营业利润 | -51,489,772.36 | -49,107,278.75 | 354,059,846.36 | 258,447,344.3 |
| 加:营业外收入 | 1,798,808.11 | 908,322.37 | 622,456.3 | 8,537,310.41 |
| 减:营业外支出 | 3,369,511.22 | 527,290.34 | 9,140,103.78 | 5,999,558.01 |
| 五、利润总额 | -53,060,475.47 | -48,726,246.72 | 345,542,198.88 | 260,985,096.7 |
| 减:所得税费用 | 46,421,694.58 | 19,136,755.54 | 156,084,177.83 | 118,882,570.14 |
| 六、净利润 | -99,482,170.05 | -67,863,002.26 | 189,458,021.05 | 142,102,526.56 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -99,482,170.05 | -67,863,002.26 | 189,458,021.05 | 142,102,526.56 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -120,652,208.04 | -69,258,725.43 | 55,280,607.97 | 50,424,910.92 |
| 少数股东损益 | 21,170,037.99 | 1,395,723.17 | 134,177,413.08 | 91,677,615.64 |
| 扣除非经常损益后的净利润 | -134,139,032.15 | -75,937,855.91 | 31,456,499.3 | 32,543,784.18 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.2 | -0.11 | 0.09 | 0.08 |
| (二)稀释每股收益 | -0.2 | -0.11 | 0.09 | 0.08 |
| 八、其他综合收益 | -1,094,094.88 | 61,323.97 | 2,915,308.12 | 2,111,576.37 |
| 归属于母公司股东的其他综合收益 | -1,008,558.78 | 56,518.06 | 2,564,784.67 | 1,897,427.7 |
| 九、综合收益总额 | -100,576,264.93 | -67,801,678.29 | 192,373,329.17 | 144,214,102.93 |
| 归属于母公司股东的综合收益总额 | -121,660,766.82 | -69,202,207.37 | 57,845,392.64 | 52,322,338.62 |
| 归属于少数股东的综合收益总额 | 21,084,501.89 | 1,400,529.08 | 134,527,936.53 | 91,891,764.31 |
| 公告日期 | 2025-08-27 | 2025-04-26 | 2025-04-26 | 2024-10-30 |
| 审计意见(境内) | | | 标准无保留意见 | |